Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5813341 | Neuropharmacology | 2016 | 11 Pages |
Abstract
The P2X7R antagonist gave rise to a less severe profile of the chronic seizure burden without suppressing the SRS frequency. More studies are needed to unravel the underlying mechanisms of the beneficial effect on seizure severity and whether the administration of the compound during early epileptogenesis could induce long-term disease-modifying effects.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Halima Amhaoul, Idrish Ali, Marco Mola, Annemie Van Eetveldt, Krystyna Szewczyk, Stephan Missault, Kenny Bielen, Samir Kumar-Singh, Jason Rech, Brian Lord, Marc Ceusters, Anindya Bhattacharya, Stefanie Dedeurwaerdere,